Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Sees Significant Drop in Short Interest

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) was the recipient of a significant decline in short interest during the month of June. As of June 30th, there was short interest totaling 143,052 shares, a decline of 84.8% from the June 15th total of 942,551 shares. Based on an average daily volume of 1,785,958 shares, the short-interest ratio is presently 0.1 days. Approximately 12.1% of the shares of the company are sold short.

Regentis Biomaterials Stock Performance

Shares of NYSEAMERICAN:RGNT traded up $0.15 on Friday, reaching $3.79. 83,556 shares of the company’s stock were exchanged, compared to its average volume of 10,333,502. Regentis Biomaterials has a fifty-two week low of $1.23 and a fifty-two week high of $15.50. The business has a 50-day simple moving average of $2.97.

Institutional Investors Weigh In On Regentis Biomaterials

A hedge fund recently bought a new stake in Regentis Biomaterials stock. AIGH Capital Management LLC bought a new position in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned about 5.79% of Regentis Biomaterials as of its most recent SEC filing.

About Regentis Biomaterials

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.